Logotipo do repositório
 

Publicação:
Fabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapy

dc.contributor.authorAlves, Renata Carolina [UNESP]
dc.contributor.authorPerosa Fernandes, Richard
dc.contributor.authorLira de Farias, Renan
dc.contributor.authorda Silva, Patricia Bento
dc.contributor.authorSantos Faria, Raquel
dc.contributor.authorQuijia, Christian Rafael [UNESP]
dc.contributor.authorGalvão Frem, Regina Célia [UNESP]
dc.contributor.authorAzevedo, Ricardo Bentes
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionFederal University of Mato Grosso (UFMT)
dc.contributor.institutionPontifícia Universidade Católica do Rio de Janeiro
dc.contributor.institutionUniversity of Brasilia (UnB)
dc.date.accessioned2023-07-29T13:45:05Z
dc.date.available2023-07-29T13:45:05Z
dc.date.issued2022-11-01
dc.description.abstractBreast cancer is the most frequent cause of cancer death in women, representing the fifth leading cause of cancer death overall. Therefore, the growing search for the development of new treatments for breast cancer has been developed lately as well as drug delivery systems such as biocompatible metal–organic Frameworks (bio-MOFs). These may be promising and attractive for drug incorporation and release. The present study aims to develop a drug carrier system RCA (bioMOF-100 submitted to the activation process) containing incorporated curcumin (CCM), whose material surface is coated with folic acid molecules (FA) to promote the targeting of drug carrier systems to the tumor region. They were synthesized and characterized using several characterization techniques. The materials were submitted to drug encapsulation tests, whose encapsulation efficiency was 32.80% for CCM@RCA-1D. Using the 1H nuclear magnetic resonance (NMR) spectroscopy technique, it was possible to verify the appearance of signals referring to folic acid, suggesting success in the functionalization of these matrices. In vitro tests such as cell viability and type of cell death were evaluated in both series of compounds (CCM@RCA-1D, CCM@RCA-1D/FA) in breast tumor lines. The results revealed low toxicity of the materials and cell death by late apoptosis. Thus, these results indicate that the matrices studied can be promising carriers in the treatment of breast cancer.en
dc.description.affiliationDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP), Rodovia Araraquara Jau, Km 01—s/n—Campos Ville
dc.description.affiliationDepartment of Chemistry Federal University of Mato Grosso (UFMT)
dc.description.affiliationDepartament of Chemical Pontifícia Universidade Católica do Rio de Janeiro
dc.description.affiliationDepartment of Genetics and Morphology Institute of Biological Sciences University of Brasilia (UnB), Campus Universitario Darcy Ribeiro—Asa Norte
dc.description.affiliationChemistry Institute São Paulo State University (UNESP), Campus Araraquara
dc.description.affiliationUnespDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP), Rodovia Araraquara Jau, Km 01—s/n—Campos Ville
dc.description.affiliationUnespChemistry Institute São Paulo State University (UNESP), Campus Araraquara
dc.identifierhttp://dx.doi.org/10.3390/pharmaceutics14112458
dc.identifier.citationPharmaceutics, v. 14, n. 11, 2022.
dc.identifier.doi10.3390/pharmaceutics14112458
dc.identifier.issn1999-4923
dc.identifier.scopus2-s2.0-85149594059
dc.identifier.urihttp://hdl.handle.net/11449/248478
dc.language.isoeng
dc.relation.ispartofPharmaceutics
dc.sourceScopus
dc.subjectbio-MOFs
dc.subjectcancer
dc.subjectcurcumin
dc.subjectdelivery systems
dc.subjectfunctionalization
dc.titleFabrication of Functional bioMOF-100 Prototype as Drug Delivery System for Breast Cancer Therapyen
dc.typeArtigopt
dspace.entity.typePublication
relation.isDepartmentOfPublicatione214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isDepartmentOfPublication.latestForDiscoverye214da1b-9929-4ae9-b8fd-655e9bfeda4b
unesp.author.orcid0000-0002-4446-3037[2]
unesp.author.orcid0000-0001-5522-7913[3]
unesp.author.orcid0000-0002-2137-9588[8]
unesp.author.orcid0000-0002-6698-0545[9]
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos